These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 23730210

  • 21. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.
    Br J Cancer; 2014 Jun 10; 110(12):2887-95. PubMed ID: 24823695
    [Abstract] [Full Text] [Related]

  • 22. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA.
    Clin Cancer Res; 2015 Nov 01; 21(21):4831-44. PubMed ID: 26124202
    [Abstract] [Full Text] [Related]

  • 23. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
    Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.
    Neoplasia; 2012 Nov 01; 14(11):1005-14. PubMed ID: 23226094
    [Abstract] [Full Text] [Related]

  • 24. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
    Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, Lin SC, Li WC.
    Oncotarget; 2015 Oct 06; 6(30):29268-84. PubMed ID: 26337468
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.
    Clin Cancer Res; 2019 Feb 15; 25(4):1156-1164. PubMed ID: 30420444
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q, Song XM, Ji YY, Jiang H, Xu LG.
    Biochem Biophys Res Commun; 2013 Nov 01; 440(4):701-6. PubMed ID: 24103749
    [Abstract] [Full Text] [Related]

  • 32. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
    Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, Teknos TN, Kumar P.
    Mol Cancer Ther; 2012 Sep 01; 11(9):1988-98. PubMed ID: 22723337
    [Abstract] [Full Text] [Related]

  • 33. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
    Bourguignon LYW, Earle C, Shiina M.
    Matrix Biol; 2019 May 01; 78-79():180-200. PubMed ID: 30077625
    [Abstract] [Full Text] [Related]

  • 34. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.
    Oncol Rep; 2011 Nov 01; 26(5):1099-109. PubMed ID: 21805039
    [Abstract] [Full Text] [Related]

  • 35. Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection.
    López RV, Levi JE, Eluf-Neto J, Koifman RJ, Koifman S, Curado MP, Michaluart-Junior P, Figueiredo DL, Saggioro FP, de Carvalho MB, Kowalski LP, Abrahão M, de Góis-Filho F, Tajara EH, Waterboer T, Boffetta P, Brennan P, Wünsch-Filho V.
    Cancer Causes Control; 2014 Apr 01; 25(4):461-71. PubMed ID: 24474236
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J, Zhang L, Zhang X, Xing X.
    J Chemother; 2015 Apr 01; 27(6):358-64. PubMed ID: 25976336
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.